News

European Medicines Verification Organisation (EMVO) would like to highlight once again the consequences following Product Withdrawal and Batch recall and remind you that these are irreversible actions.

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which looks back on the past four years of the verification system’s operation, informs about the launch of the European Alert Management System (EAMS) and provides an opportunity to look into the first European Medicines Verification System’s (EMVS) forum, which was also attended by the Latvian Medicines Verification Organisation (LZVO) representatives Inese Erdmane and Andra Pučko.

On February 22, the Latvian Medicines Verification Organisation (LZVO) held a free seminar for manufacturers of medicines or marketing authorization holders (MAH) on the current developments related to the medicines verification system in Latvia and a look back on what was done in 2022.

To inform marketing authorization holders (MAHs) about the current events, the Latvian Medicines Verification Organisation (LZVO) will hold a special seminar on February 22, 2023.

Summarizing what was done in 2022 and outlining the plans for 2023, the European Medicines Verification Organisation (EMVO) in cooperation with the National Medicines Verification Organisations has published the EMVS Community Newsletter – 2022 Holiday Bulletin edition. In this bulletin, Inese Erdmane, Chairwoman of the Board at the Latvian Medicines Verification Organisation (LZVO), also talks about this year's achievements.